◆英語タイトル:Revance Therapeutics Inc (RVNC) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY0983
◆発行会社(調査会社):
GlobalData
◆発行日:2020年1月
◆ページ数:49
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Revance Therapeutics Inc (RVNC) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Revance Therapeutics Inc (Revance Therapeutics) is a biotechnology company that develops, manufactures and markets novel botulinum toxin products. It is investigating its lead candidate, daxibotulinumtoxinA, a topical gel formulation as a needle-free approach for a wide range of therapeutic and aesthetic indications, such as facial wrinkles, chronic migraine, and muscle disorders. The company is also advancing daxibotulinumtoxinA for injection (DAXI), an injectable formulation of botulinum toxin for the treatment of glabellar lines, cervical dystonia, and plantar fasciitis. It employs its proprietary peptide excipient technology to advance the development of its novel neuromodulators portfolio. Revance Therapeutics is headquartered in Newark, California, the US.
Revance Therapeutics Inc Key Recent Developments
Jan 09,2020: Revance provides corporate update and anticipated milestones for 2020
Dec 02,2019: Revance Promotes Dustin Sjuts to chief commercial officer, Aesthetics & Therapeutics
Nov 04,2019: Revance reports third quarter 2019 financial results, provides corporate update
Oct 14,2019: Revance appoints Mark J. Foley as President and CEO, replacing Dan Browne
Oct 02,2019: Revance earns Great Place to Work Certification for Second Year
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Revance Therapeutics Inc – Key Facts
Revance Therapeutics Inc – Key Employees
Revance Therapeutics Inc – Key Employee Biographies
Revance Therapeutics Inc – Major Products and Services
Revance Therapeutics Inc – History
Revance Therapeutics Inc – Company Statement
Revance Therapeutics Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Revance Therapeutics Inc – Business Description
R&D Overview
Revance Therapeutics Inc – Corporate Strategy
Revance Therapeutics Inc – SWOT Analysis
SWOT Analysis – Overview
Revance Therapeutics Inc – Strengths
Revance Therapeutics Inc – Weaknesses
Revance Therapeutics Inc – Opportunities
Revance Therapeutics Inc – Threats
Revance Therapeutics Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Revance Therapeutics Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Jan 09, 2020: Revance provides corporate update and anticipated milestones for 2020
Dec 02, 2019: Revance Promotes Dustin Sjuts to chief commercial officer, Aesthetics & Therapeutics
Nov 04, 2019: Revance reports third quarter 2019 financial results, provides corporate update
Oct 14, 2019: Revance appoints Mark J. Foley as President and CEO, replacing Dan Browne
Oct 02, 2019: Revance earns Great Place to Work Certification for Second Year
Aug 05, 2019: Revance reports second quarter 2019 financial results, provides corporate update
Jul 17, 2019: Revance adds life sciences audit executive Chris Nolet to board of directors
Jun 06, 2019: Revance adds iconic brand Builder Jill Beraud to Board of Directors
May 08, 2019: Revance reports first quarter 2019 financial results and provides corporate update
Apr 09, 2019: Revance appoints former Allergan marketing veteran Taryn Conway as Vice President of marketing
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Revance Therapeutics Inc, Key Facts
Revance Therapeutics Inc, Key Employees
Revance Therapeutics Inc, Key Employee Biographies
Revance Therapeutics Inc, Major Products and Services
Revance Therapeutics Inc, History
Revance Therapeutics Inc, Subsidiaries
Revance Therapeutics Inc, Key Competitors
Revance Therapeutics Inc, Ratios based on current share price
Revance Therapeutics Inc, Annual Ratios
Revance Therapeutics Inc, Annual Ratios (Cont...1)
Revance Therapeutics Inc, Interim Ratios
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Revance Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Revance Therapeutics Inc, Performance Chart (2014 - 2018)
Revance Therapeutics Inc, Ratio Charts
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020